RJA
ACHL

Raymond James & Associates’s Achilles Therapeutics ACHL Stock Holding History

Raymond James & Associates’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,105
Closed -$11.9K – 3970
2023
Q3 		$11.9K Buy
13,105
+9
+0.1% +$9 ﹤0.01% 3755
2023
Q2 		$12.4K Buy
+13,096
New +$12.4K ﹤0.01% 3801

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FA
Forefront Analytics West Conshohocken, Pennsylvania $110M AUM 18.54% 1-Year Est. Return

Raymond James & Associates's ACHL Position: Q4 2023 in Review

Raymond James & Associates sold out of Achilles Therapeutics (ACHL) in Q4 2023, closing a stake of 13,105 shares — an estimated $11.9K sold.

Raymond James & Associates first reported a position in ACHL in Q2 2023 and held it in 2 quarters. The position peaked at $12.4K in Q2 2023. 20 funds tracked by Wall St. Rank hold ACHL as of Q4 2023.

  • Raymond James & Associates reported no remaining Achilles Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Raymond James & Associates sold 13,105 Achilles Therapeutics shares in Q4 2023, an estimated $11.9K.
  • Raymond James & Associates first reported a position in Achilles Therapeutics in Q2 2023 and held it in 2 quarters.
  • Raymond James & Associates's Achilles Therapeutics position peaked at $12.4K in Q2 2023.
  • 20 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q4 2023.

Based on Raymond James & Associates's 13F filing for Q4 2023, filed 16 Jan 2024.